Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect
10:00am, Sunday, 02'nd Feb 2025
NEW YORK CITY, NY / ACCESS Newswire / February 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Compa
NEW YORK CITY, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Compa
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious meta
NEW YORK CITY, NY / ACCESS Newswire / January 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. ("Akero" or "the Compa
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
11:16am, Wednesday, 29'th Jan 2025
Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead product candidate, EFX.
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
09:30pm, Tuesday, 28'th Jan 2025
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo
Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients
02:38pm, Tuesday, 28'th Jan 2025
Company's stock surged over 100% after positive 96-week results from its phase 2b SYMMETRY study using EFX to treat F4 compensated cirrhosis due to MASH patients. The company achieved a significant re
Akero Therapeutics Announces Proposed Public Offering of Common Stock
04:01pm, Monday, 27'th Jan 2025
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabo
Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results
12:10pm, Monday, 27'th Jan 2025
Shares of Akero Therapeutics (AKRO) doubled Monday when the pharmaceutical firm that focuses on metabolic illnesses reported positive results from a study of its experimental treatment for liver disea
Why did Akero (AKRO) stock soar 110% on Monday?
11:30am, Monday, 27'th Jan 2025
Akero Therapeutics Inc (NASDAQ: AKRO) says its candidate treatment for a serious liver disease demonstrated exceptional safety and efficacy in a Phase 2b study.
Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH Study
09:05am, Monday, 27'th Jan 2025
Akero Therapeutics doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH obliterated expectations. The post Akero Therapeutics Stock Doubles — Pulling 89bio Hi
Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why
09:01am, Monday, 27'th Jan 2025
On Monday, Akero Therapeutics, Inc. AKRO released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX)
Akero shares double after preliminary results from mid-stage trial for liver disease drug
06:52am, Monday, 27'th Jan 2025
Akero Therapeutics shares gained 106% before the bell on Monday after the company reported results from a mid-stage trial studying its lead drug in patients with a type of liver disease.
Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 24% effect size over pl
Investor webcast on Monday, January 27, 2025, at 8:00 a.m. ET to present clinical data SOUTH SAN FRANCISCO, Calif.
